RVPH Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Reviva Pharmaceuticals Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.24 |
| 52 Week High | US$5.67 |
| 52 Week Low | US$0.60 |
| Beta | -0.055 |
| 11 Month Change | 26.85% |
| 3 Month Change | 10.71% |
| 1 Year Change | -67.67% |
| 33 Year Change | -66.03% |
| 5 Year Change | -88.12% |
| Change since IPO | -87.23% |
Recent News & Updates
Recent updates
Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely
Aug 24
We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate
Dec 28Reviva Pharmaceuticals drops 9% on $8.5M private placement
Sep 06We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate
Aug 24Reviva Pharmaceuticals Q2 GAAP loss per share widens
Aug 15Reviva reports positive brilaroxazine results in Aacute Schizophrenia
Apr 26Shareholder Returns
| RVPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 8.8% | 2.8% | 1.0% |
| 1Y | -67.7% | 13.3% | 31.4% |
Return vs Industry: RVPH underperformed the US Pharmaceuticals industry which returned 13.3% over the past year.
Return vs Market: RVPH underperformed the US Market which returned 31.4% over the past year.
Price Volatility
| RVPH volatility | |
|---|---|
| RVPH Average Weekly Movement | 16.1% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RVPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RVPH's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 15 | Laxminarayan Bhat | www.revivapharma.com |
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity.
Reviva Pharmaceuticals Holdings, Inc. Fundamentals Summary
| RVPH fundamental statistics | |
|---|---|
| Market cap | US$41.47m |
| Earnings (TTM) | -US$33.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs RVPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$33.01m |
| Earnings | -US$33.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -0.8% |
How did RVPH perform over the long term?
See historical performance and comparison